BURLINGAME, Calif. - Enliven Therapeutics, Inc. (NASDAQ:ELVN) will host a webcast conference call on Thursday, June 11, 2026 at 8:30 a.m. ET to discuss updated data from its Phase 1 ENABLE clinical trial, according to a press release statement.
The trial evaluates ELVN-001 in patients with previously treated chronic myeloid leukemia. Data will be presented at the European Hematology Association 2026 Congress taking place June 11-14 in Stockholm, Sweden.The company’s stock has experienced significant volatility, declining 14% over the past week despite posting strong gains of 69% over six months and 131% year-to-date. Trading at $36.03 with a market capitalization of $2.18 billion, the stock currently sits 26% below its 52-week high of $48.53.
The EHA Congress oral presentation is scheduled for Thursday, June 11, at 5:45 p.m. CEST / 11:45 a.m. ET. Dennis Kim, M.D. will present the findings titled "ENABLE: Updated Efficacy and Safety Results of ELVN-001, a Novel Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML."
The ENABLE study is a Phase 1 dose escalation and expansion trial designed to evaluate safety and tolerability of ELVN-001 in patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to tyrosine kinase inhibitors. The trial includes patients with and without T315I mutations. Secondary endpoints include pharmacokinetics, major molecular response, duration of response, BCR::ABL1 transcript levels and complete hematologic response.
ELVN-001 is a small molecule kinase inhibitor designed to target the BCR::ABL gene fusion in patients with chronic myeloid leukemia. The compound was designed to have activity against the T315I mutation, which confers resistance to most approved tyrosine kinase inhibitors.
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. According to InvestingPro analysis, the company holds more cash than debt on its balance sheet and maintains liquid assets exceeding short-term obligations. The stock appears overvalued based on InvestingPro’s Fair Value assessment. Analysts maintain a consensus "Strong Buy" rating with price targets ranging from $45 to $80.
In other recent news, Enliven Therapeutics has been the focus of several notable developments. The company reported its first-quarter 2026 results, prompting Mizuho to raise its price target from $45 to $62 while maintaining an Outperform rating. Enliven is set to present updated data from its Phase 1 ENABLE trial of ELVN-001 for chronic myeloid leukemia at the European Hematology Association Congress. The trial data previously showed a major molecular response rate of 47% in one cohort, with 52% in patients who had prior treatment with asciminib. Guggenheim initiated coverage on Enliven with a buy rating and an $80 price target, highlighting the potential of ELVN-001, which is expected to be Phase 3-ready this summer. H.C. Wainwright reiterated its Buy rating and increased its price target to $56 following the announcement of Merck’s acquisition of Terns Pharmaceuticals. The acquisition, valued at approximately $6.7 billion, is anticipated to close next quarter. These developments underscore the growing interest and confidence in Enliven’s therapeutic innovations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.